Natural History Studies in NCL and Their Expanding Role in Drug Development: Experiences From CLN2 Disease and Relevance for Clinical Trials

Исследования естественного течения НЦЛ и их расширяющаяся роль в разработке лекарственных средств: опыт при заболевании CLN2 и значение для клинических исследований
Angela Schulz, Miriam Nickel
2022-02-08

CLN2 diseaseNCL disease registrycerliponase alphanatural history studiesnatural-history controls
Conducting clinical trials in rare diseases is challenging. In trials that aim to use natural history control cohorts for evaluation of efficacy, lack of data on natural history of disease prolongs development of future therapies significantly. Therefore, collection of valid natural history data in clinical settings is needed to advance drug development. These data need to fulfill requirements on type of collection, quantifiable measures on the course of disease, verification and monitoring as well as compliance to strict data protection and sharing policies. Disease registries can be a source for patient data. Late-infantile CLN2 disease is characterized by rapid psychomotor decline and epilepsy. Natural-history data of 140 genotype-confirmed CLN2 patients from two independent, international cohorts were analyzed in a natural history study. Both datasets included quantitative ratings with disease-specific clinical scores. Among 41 patients for whom longitudinal assessments spanning an extended disease course were available within the DEM-CHILD DB (an international NCL disease patient database, NCT04613089), a rapid loss of motor and language abilities was documented in quantitative detail. Data showed that the course of disease in late-infantile CLN2 disease is highly predictable with regard to the loss of language and motor function and that the results were homogeneous across multiple and international sites. These data were accepted by EMA and FDA as valid natural-history controls for the evaluation of efficacy in experimental therapies for CLN2 disease and led to an expedited approval of intracerebroventricular enzyme replacement therapy with cerliponase alpha in May 2017.
1
Analysis of 140 genotype-confirmed CLN2 patients from two independent international cohorts characterized disease progression using quantitative, disease-specific clinical scores.
2
EMA and FDA accepted the CLN2 natural-history cohorts as valid efficacy controls, supporting expedited approval of intracerebroventricular cerliponase alfa in May 2017.
3
Longitudinal data from 41 patients demonstrated rapid and quantitatively predictable loss of motor and language abilities in late-infantile CLN2 disease, with homogeneous progression across international sites.
4
Natural-history data must include standardized collection methods, quantifiable disease-course measures, verification, monitoring, and compliant data protection and sharing.
5
Validated natural-history data are essential for shortening rare-disease drug development when randomized or untreated control groups are difficult to obtain.

late-infantile CLN2 disease

the predictable longitudinal decline of language and motor function, and its use as a natural-history control for evaluating experimental therapies

Publication Details
Publication Date
2022-02-08
Journal
Publisher
ISSN
Cited by
26
Access Type
Author Information
Authors
Angela Schulz
Miriam Nickel
Explore further
Open the scid.ai AI chat with a ready-made request: it will find papers on a similar topic and help build a literature review.
Find similar papers in the chat →
Make a presentation
100%